HDAC9 and neoplasm: In the context of cancer therapy, the use of DNA methylation inhibitors and histone deacetylase (HDAC) inhibitors has demonstrated the potential to activate tumor-suppressor genes and halt tumor growth, as evidenced by the results of animal studies and selected clinical trials Nevertheless, it is evident that comprehensive disruption of epigenetic programming may result in both beneficial and detrimental alterations in gene expression.